This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ACI-91

AC Immune, Ltd.

Drug Names(s): PSY 130/131

Description: ACI-91 is an orally administered, muscarinic acetylcholine inhibitor which indirectly down-regulates the expression and activity of the beta-secretase BACE-1 in pre-clinical studies.

Deal Structure: ACI-91 was in-licensed by AC Immune from an unnamed company, presumably Prosteosys AG. According to Prosteosys, PSY-130/131 was a reprofiled molecule for Alzheimer's disease that was outlicensed to AC Immune.

Partners: ProteoSys AG


ACI-91 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug